IMRICOR MEDICAL SYSTEMS INC (IMR)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

IMR

IMR - IMRICOR MEDICAL SYSTEMS INC

FNArena Sector : Medical Equipment & Devices
Year End: December
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -1.15
Index: ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$1.68

11 Jun
2026

0.000

OPEN

$1.68

0.000

HIGH

$1.69

281,871

LOW

$1.64

TARGET
$2.61 55.4% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CTE . CU6 . CVB . CYC . EBR . EMV . EYE . FPH . IME . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RAP . RMD . SHG . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
IMR: 1
Title FY26
Forecast		 FY27
Forecast
EPS (cps) - 6.7 xxx
DPS (cps) 0.0 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio N/A xxx
Dividend Yield 0.0% xxx
Div Pay Ratio(%) N/A xxx
This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: N/A

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 N/A

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx-12.7
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx0.5 M
Book Value Per Share xxxxxxxxxxxxxxx5.4
Net Operating Cash Flow xxxxxxxxxxxxxxx-29.6 M
Net Profit Margin xxxxxxxxxxxxxxx-8,661.57 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx-1,463.63 %
Return on Invested Capital xxxxxxxxxxxxxxx-131.50 %
Return on Assets xxxxxxxxxxxxxxx-75.84 %
Return on Equity xxxxxxxxxxxxxxx-1,463.63 %
Return on Total Capital xxxxxxxxxxxxxxx-89.98 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-30.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx18 M
Long Term Debt xxxxxxxxxxxxxxx21 M
Total Debt xxxxxxxxxxxxxxx39 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx61 M
Price To Book Value xxxxxxxxxxxxxxx28.42

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx0.7 M
Capex % of Sales xxxxxxxxxxxxxxx148.57 %
Cost of Goods Sold xxxxxxxxxxxxxxx4 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx32 M
Research & Development xxxxxxxxxxxxxxx17 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

29/05/2026

1

Speculative Buy

$2.61

55.36%

With several near-term positive catalysts on the horizon, Morgans believes Imricor Medical Systems can be re-rated.

The med-tech company is commercialising its MRI-guided cardiac ablation which incorporates a fully integrated system, the analyst explains, including equipment, consumables and software.

Notably, the US atrial flutter trial is moving towards FDA approval in 2H2026 and the trial of the ventricular tachycardia is happening in Europe.

Post the $60m capital raise, Imricor has a proforma cash balance of $108m. EPS estimates are raised 10.1% for FY26 and 19.5% for FY28.

Target price moves to $2.61 from $2.63, previously on some share dilution and changes to the discounted cash flow model.

Speculative Buy rating maintained.

FORECAST
Morgans forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -6.65 cents.
Morgans forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -4.43 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

3

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Taylor Collison

xx/xx/xxxx

2

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Jarden

25/05/2026

1

Buy

$3.30

96.43%

Jarden initiates coverage on Imricor Medical Systems with a Buy rating and a $3.30 target price.

The company has developed the sole magnetic resonance imaging-compatible cardiac ablation platform, addressing a major structural deficiency within conventional electrophysiology.

The proprietary technology allows procedures to occur inside a scanner in real-time, utilising 3D mapping and navigation to correlate catheter tracking with anatomical and scar tissue visualisations.

Bypassing the soft-tissue blindness of standard X-ray fluoroscopy guidance delivers superior clinical outcomes, faster procedure times, and eliminates radiation exposure at a lower overall cost, the report points out.

Widespread industry adoption of interventional cardiac magnetic resonance imaging is considered inevitable.

FORECAST
Jarden forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -10.79 cents.
Jarden forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -10.20 cents.

Canaccord Genuity

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Extra Coverage Research History >

IMR STOCK CHART

FNArena News on IMR

1
Australian Broker Call *Extra* Edition – May 25, 2026

May 25 2026 - Daily Market Reports
2
In Brief: Imricor, COG Financial & Alicantro

May 22 2026 - Weekly Reports
3
Australian Broker Call *Extra* Edition – May 21, 2026

May 21 2026 - Daily Market Reports
4
Australian Broker Call *Extra* Edition – May 19, 2026

May 19 2026 - Daily Market Reports
5
Next Week At A Glance – 4-8 May 2026

May 01 2026 - Weekly Reports

Latest Medical Equipment & Devices News

1
Treasure Chest: Pro Medicus

Jun 04 2026 - Treasure Chest
2
Cochlear’s Shock Downgrade Raises Concerns

Apr 23 2026 - Australia
3
GLP-1s Drive Strong Quarter For ResMed

Feb 02 2026 - Australia
4
ImpediMed Ready To Scale Up

Dec 16 2025 - Small Caps
5
Fisher & Paykel Healthcare’s Superior Profile

Dec 02 2025 - Australia
6
4DMedical Poised For A Recovery

Nov 25 2025 - Technicals
7
Treasure Chest: Pro Medicus

Nov 12 2025 - Treasure Chest
8
Tariff Uncertainty Negates ResMed’s Q1 Positives

Nov 05 2025 - Australia
9
Acquisition Loads Up Catapult

Oct 20 2025 - Small Caps
10
Cochlear’s Future In Nexa’s Hands

Aug 19 2025 - Australia